Changchun BCHT Biotechnology Co. (SHA:688276)
17.36
-0.26 (-1.48%)
May 20, 2026, 1:05 PM CST
SHA:688276 Revenue
Changchun BCHT Biotechnology Co. had revenue of 147.35M CNY in the quarter ending March 31, 2026, a decrease of -9.21%. This brings the company's revenue in the last twelve months to 590.13M, down -47.36% year-over-year. In the year 2025, Changchun BCHT Biotechnology Co. had annual revenue of 605.07M, down -50.77%.
Revenue (ttm)
590.13M
Revenue Growth
-47.36%
P/S Ratio
12.35
Revenue / Employee
471.35K
Employees
1,252
Market Cap
7.29B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 605.07M | -624.01M | -50.77% |
| Dec 31, 2024 | 1.23B | -595.60M | -32.64% |
| Dec 31, 2023 | 1.82B | 753.24M | 70.30% |
| Dec 31, 2022 | 1.07B | -130.58M | -10.86% |
| Dec 31, 2021 | 1.20B | -239.33M | -16.60% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Northeast Pharmaceutical Group | 7.13B |
| China Animal Husbandry Industry | 6.45B |
| Jiangsu Kanion Pharmaceutical | 3.25B |
| Tianjin Tianyao Pharmaceuticals | 2.73B |
| Jiuzhitang | 2.40B |
| HARBIN GLORIA PHARMACEUTICALS Co., LTD | 2.12B |
| Guangxi Wuzhou Zhongheng Group | 1.58B |
| Hunan Warrant Pharmaceutical Co.,Ltd | 1.49B |